| Antithyroid drug-induced vasculitides (n = 4) | Antithyroid drug-induced LLD (n = 12) |
---|---|---|
Age, years (range) | 35 ± 6 (20–40) | 30 ± 8 (25–52) |
Female | 3 (75) | 12 (100) |
Graves' disease | 4 (100) | 9 (75) |
Hashimoto thyroiditis | 0 | 3 (25) |
Florid hyperthyroidism | 4 (100) | 3 (25) |
Relapse of hyperthyroidism | 2 (50) | 4 (33.3) |
Antimicrosomal Ab | 3 (75) | 10 (83.3) |
Antithyroid drug therapy, months | 21 ± 6 | 18 ± 7 |
Months between first complaints and ANCA detection | 3 ± 1.5 | 2 ± 1 |
Propylthiouracil | 2 (50) | 10 (83.3) |
Methimazole | 2 (50) | 2 (16.7) |
Renal manifestations | 2 (50) | 1 (8.3) |
Lung manifestations | 3 (75) | 0 |
Skin manifestations | 0 | 10 (83.3) |
PANCA | 3 (75) | 12 (100) |
CANCA | 1 (25) | 0 |
MPO-ANCA (U/ml) | 65 ± 20 | 53 ± 15 |
PR3-ANCA (U/ml) | 44 | - |
ANA | 0 | 8 (66.6) |
aCL IgG, IgM | 0 | 9 (75) |
Anti-β2 GP I IgG, IgM | 0 | 4 (33.3) |
Cryoglobulinemia | 0 | 3 (25) |
Low C4 (<0.1 g/l) | 0 | 3 (25) |
High CR-P (>10 mg/l) | 4 (100) | 4 (33.3) |
Leucopenia (<3 × l09/l) | 0 | 2 (16.7) |